Overview

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.

Phase:

Phase 2

Details

Lead Sponsor:

QuatRx Pharmaceuticals Company

Collaborator:

Hormos Medical

Treatments:

Phosphodiesterase 5 Inhibitors
Tamoxifen